Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. Hulgan T, Rosenbloom ST, Hargrove F, Talbert DA, Arbogast PG, Bansal P, Miller RA, Kernodle DS (2004) J Intern Med 256: 349-57 A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A (2012) J Antimicrob Chemother 67: 819-31 A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. Elsea SH, Hsiung Y, Nitiss JL, Osheroff N (1995) J Biol Chem 270: 1913-20 Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) J Biol Chem 274: 35927-32 Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N (1991) J Biol Chem 266: 14585-92 Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. Elsea SH, Osheroff N, Nitiss JL (1992) J Biol Chem 267: 13150-3 A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. Hsiung Y, Elsea SH, Osheroff N, Nitiss JL (1995) J Biol Chem 270: 20359-64 Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme. Corbett AH, Hong D, Osheroff N (1993) J Biol Chem 268: 14394-8 Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect. Ambrose PG, VanScoy BD, Luna BM, Yan J, Ulhaq A, Nielsen TB, Rudin S, Hujer K, Bonomo RA, Actis L, Skaar E, Spellberg B (2019) Antimicrob Agents Chemother 63: Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N (1992) Antimicrob Agents Chemother 36: 751-6 Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N (1993) Antimicrob Agents Chemother 37: 2179-86 NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE (2014) Antimicrob Agents Chemother 58: 2657-64 High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR (2014) Antimicrob Agents Chemother 58: 3270-5 Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR (2013) Int J Antimicrob Agents 42: 232-7 High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR (2012) J Clin Microbiol 50: 1390-6 Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N (1997) Biochemistry 36: 2919-24 Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Robinson MJ, Corbett AH, Osheroff N (1993) Biochemistry 32: 3638-43 Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Bromberg KD, Burgin AB, Osheroff N (2003) Biochemistry 42: 3393-8 Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (2000) Biochemistry 39: 2726-32 Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance. Blackman A, May S, Devasia RA, Maruri F, Stratton C, Sterling TR (2012) Eur J Clin Microbiol Infect Dis 31: 2177-82 Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions: a pilot study. Khan W, Sullivan KL, McCann JW, Gonsalves CF, Sato T, Eschelman DJ, Brown DB (2011) AJR Am J Roentgenol 197: W343-5 A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis. Van Der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR (2015) Epidemiol Infect 143: 960-5 Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes. Osheroff N, Corbett AH, Elsea SH, Westergaard M (1994) Cancer Chemother Pharmacol 34 Suppl: S19-25 Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Sterling TR (2016) Int J Tuberc Lung Dis 20: 42-47 Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, Sterling TR (2012) Int J Tuberc Lung Dis 16: 1162-7 Fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli from the milk of cows with clinical mastitis in Southern Taiwan. Su Y, Yu CY, Tsai Y, Wang SH, Lee C, Chu C (2016) J Microbiol Immunol Infect 49: 892-901
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.